Why this drug is interesting

Prussian blue is a pigment — the blue of blueprints and of Hokusai's wave — repurposed as an antidote. It is not absorbed, has no systemic pharmacology worth the name, and works purely as a resin sitting in the gut lumen exchanging its potassium for thallium. It is the recommended treatment for one of the most feared poisonings in toxicology, and the honest evidence for it in humans is thin.

Thallium is worth understanding before its antidote. Thallium salts are "rapidly and nearly completely absorbed by virtually all routes", and enter cells by a unique process governed by thallium's similarity in charge and ionic radius to potassium — which is the key to both the toxicity and the treatment.¹

Pharmacology

Mechanism

Prussian blue is a lattice of ferric and ferrocyanide ions with potassium sitting in the interstices. Thallium, chemically a potassium mimic, exchanges into those sites and is held. Because the resin is not absorbed, the captured thallium stays in the gut lumen and leaves in the stool.

The reason this matters more than simple decontamination is that thallium undergoes enterohepatic recirculation — it is secreted back into the gut after absorption. A luminal binder therefore keeps working long after the ingestion, intercepting thallium on each pass. That is why Prussian blue is given for days to weeks rather than as a one-off dose, and why it is useful even when the ingestion was not recent.

Soluble versus insoluble

The evidence and the product do not match

This is the central problem with Prussian blue and it is rarely stated plainly. Thompson and Callen reviewed the literature and found that "the majority of evidence describing the efficacy of Prussian blue for radiocesium poisoning is based on the use of the insoluble form. In contrast, the majority of data supporting the efficacy of Prussian blue in thallium poisoning involves the use of the soluble form."² The product licensed in the US is the insoluble form, approved for both indications — and "while there is sufficient evidence that the insoluble form … is effective in radiocesium poisoning, there is a paucity of analogous data supporting its use in thallium poisoning". Whether the physicochemical difference changes human outcomes "is not known".²

Dosing

What can be said about the shape of treatment: it is oral (or via nasogastric tube), given in divided doses through the day, and continued for a prolonged period — driven by the enterohepatic recirculation described above rather than by the time since ingestion. Treatment is monitored against urinary thallium excretion and clinical progress.

If Prussian blue cannot be obtained

Activated charcoal is the realistic fallback, and it is a reasonable one. In a standard isotherm model, maximal adsorptive capacities for thallium were activated charcoal 59.7 mg/g and Prussian blue 72.7 mg/g — a real but not enormous difference — and at a physiological potassium concentration both were essentially unchanged (58.3 and 69.8 mg/g).³ Hoffman's review notes that single- or multiple-dose activated charcoal is supported by in vitro binding and some animal data, and that charcoal haemoperfusion may be a useful adjunct.¹ See activated charcoal.

What not to do in thallium poisoning

Practical use in the ED

Consider the diagnosis at all. Painful ascending sensory neuropathy plus constipation, with alopecia arriving later, in a patient with a plausible exposure. Thallium is a deliberate-poisoning agent as often as an industrial one.
Call NPIS on 0344 892 0111 immediately — for advice, for confirmatory analysis, and to find stock.
Give activated charcoal while you are finding Prussian blue. It binds thallium respectably and is available now.¹³
Do not give dimercaprol or penicillamine, and do not force potassium diuresis.¹
Involve critical care early in severe cases; the neuropathy can progress to respiratory involvement.
Think about who else is exposed and about the source — deliberate thallium poisoning has forensic implications, and a case may need police involvement alongside public health.

Critical appraisal

That is an unusually candid basis for a first-line recommendation: not that it is proven to work in humans, but that the animal data are supportive, the alternatives are worse or harmful, and it is very safe. It is a defensible position — a non-absorbed resin with a benign profile, in a poisoning with high mortality and no better option, does not need a randomised trial to justify a trial of therapy. But it should be stated as what it is.

Stack the two evidence problems together and the picture sharpens: there are no controlled human trials at all, and the human data that do exist for thallium mostly concern a different physical form of the compound from the one that is manufactured.¹² The reasonable conclusion is not that Prussian blue should be withheld — it should not — but that its reputation as "the antidote for thallium" carries more certainty than the literature does.

Hoffman's closing recommendation is worth repeating because it is the intervention with the best evidence of all: "Public health efforts should focus on greater restrictions on access to, and use of, thallium salts."¹

References

1
Hoffman RS. Thallium toxicity and the role of Prussian blue in therapy. Toxicological Reviews 2003;22(1):29–40. PubMed 14579545. The backbone of this page. Source of the absorption and potassium-mimicry description, the ascending painful sensory neuropathy and alopecia, the constipation-rather-than-diarrhoea point, the placental transfer and fetal effects, the evidence against dimercaprol and penicillamine including CNS redistribution, the harm of forced potassium diuresis, the charcoal and haemoperfusion position, and the quoted conclusion that human efficacy data are insufficient but that Prussian blue is the drug of choice on safety grounds. Abstract read 6 September 2026.
2
Thompson DF, Callen ED. Soluble or insoluble prussian blue for radiocesium and thallium poisoning? The Annals of Pharmacotherapy 2004;38(9):1509–1514. PubMed 15252192. Source of the soluble/insoluble mismatch: the thallium evidence is predominantly for the soluble form while the form approved in the US is insoluble, the data supporting insoluble Prussian blue in thallium are sparse, and whether the difference affects human outcomes is not known. Abstract read 6 September 2026.
3
Hoffman RS, Stringer JA, Feinberg RS, Goldfrank LR. Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. Journal of Toxicology: Clinical Toxicology 1999;37(7):833–837. PubMed 10630266. In vitro isotherm study. Source of the maximal adsorptive capacities — activated charcoal 59.7 mg/g, Prussian blue 72.7 mg/g, sodium polystyrene sulfonate 713 mg/g — and of the collapse of sodium polystyrene sulfonate to 39.1 mg/g at physiological potassium while the other two were essentially unchanged. In vitro only; no human outcomes. Abstract read 6 September 2026.
4
electronic Medicines Compendium. medicines.org.uk/emc. Searched 6 September 2026 for prussian blue, Radiogardase and ferric hexacyanoferrate: all three return a "No search results" page. No SmPC is published for Prussian blue in the UK, so none can be cited. The emc is an industry-hosted compendium of published SmPCs and PILs, not the MHRA register — this establishes that no SmPC is published, rather than that no marketing authorisation exists anywhere.
5
National Poisons Information Service. TOXBASE · NPIS 0344 892 0111. Required, and this page deliberately gives no dose. For a poisoning this rare NPIS is also the practical route to locating stock of an unlicensed antidote.

Prussian Blue

At a glance